Mariana B. De Oliveira
Sao Paulo, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Journal: Biochemical and biophysical research communications
Published: August 26, 2019
Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism.
Journal: Scientific reports
Published: August 23, 2018
Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
Journal: Current molecular medicine
Published: July 12, 2018
Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly.
Journal: Cancer immunology, immunotherapy : CII
Published: May 06, 2018
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Journal: Cancer letters
Published: February 24, 2017
TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line.
Journal: Biochimica et biophysica acta
Published: February 02, 2016
Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.
Journal: Leukemia & lymphoma
Published: July 27, 2013
Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant.
Journal: Leukemia & lymphoma
Published: February 13, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026